A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 21, 2025

Primary Completion Date

July 5, 2027

Study Completion Date

July 5, 2029

Conditions

Peripheral T Cell Lymphoma

Interventions

DRUG

Golidocitinib

150 mg once per day by PO

DRUG

Cyclophosphamide

750 mg/m2 by IV

DRUG

Doxorubicin

50 mg/m2 by IV

DRUG

Vincristine

1.4 mg/m2 (max: 2 mg) by IV

DRUG

Prednisone

100 mg by PO

Trial Locations (1)

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER